Local tissue tolerability of meloxicam, a new NSAID: Indications for parenteral, dermal and mucosal administration

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 44-50

  Stei, P ^a   Kruss, B ^a   Wiegleb, J ^a   Trach, V ^b  

^a Department of Experimental Pathology ^*  (Germany)

^b Basotherm GmbH   (Germany)

Author keywords

Eye drops; Gel; Injection; Local tolerance; Meloxicam; Suppositories

Indexed keywords

DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GUINEA PIG; HEMOLYSIS; HISTOPATHOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; RECTAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE NECROSIS; TOPICAL DRUG ADMINISTRATION; TOXICITY;

EID: 0029919836     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.44     Document Type: Article

References (11)

1. Nuutinen LS, Laitinen JO, Salomaki TE. A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain. Drug Safety 1993;9:380-93.
2. Vaccarino V, Sirtori CR, Bufalino L. Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers. Curr Ther Res 1989;45:1-13.
3. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996;35(suppl. 1):35-8.
4. Lund B, Distel M, Bluhmki E. A double-blind placebo controlled study of three different doses of meloxicam in patients with osteoarthritis (OA) of the knee. Scand J Rheumatol 1994;Suppl 98:abstract no. 117.
5. Huskisson EC, Narjes H, Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994;Suppl 98:abstract no. 115.
6. Brown S, Templeton L, Prater DA, Potter CJ. Use of an in vitro haemolysis test to predict tissue irritancy in an intramuscular formulation. J Patenter Sci Technol 1989;43:117-20.
7. Oshida S, Degawa K, Takahashi Y, Akaishi S. Physicochemical properties and local toxic effects of injectables. Tohoku J Exp Med 1979;127:301-16.
8. Surber C, Dubach, UC. Tests for local toxicity of intramuscular drug preparations. Comparison of in vivo and in vitro findings. Armeim Forsch Drug Res 1989;3:1586-9.
9. Draize JH, Wodard G, Cedvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 1944;82:377-90.
10. Svendsen U, Rasmussen F, Nielsen P, Steiness E. The loss of creatine kinase (CK) from intramuscular injection sites in rabbits. A predictive tool for local toxicity. Acta Pharmacol Toxicol 1979;44:324-8.
11. Cingolani E, Cingolani G, Mosconi P, Coppi G. Local tolerance evaluation of intramuscular drug preparations. II. Farmaco Ed Pr 1986;41:89-97.